Rozalyn Milne1, Morgan Price2, Bruce Wallace3, Anne Drost4, Irene Haigh-Gidora4, Frank A Nezil4, Chris Fraser2. 1. Cool Aid Community Health Centre, 1st Floor 713 Johnson Street, Victoria, BC, Canada V8W 1M8. Electronic address: rmilne@coolaid.org. 2. UBC Department of Family Practice, Cool Aid Community Health Centre, 1st Floor 713 Johnson Street, Victoria, BC, Canada V8W 1M8. 3. School of Social Work, University of Victoria, Box 1700 STN CSC, Victoria, BC, Canada V8W 2Y2. 4. Cool Aid Community Health Centre, 1st Floor 713 Johnson Street, Victoria, BC, Canada V8W 1M8.
Abstract
BACKGROUND: Knowledge is increasing regarding effective models of HCV care for people who inject drugs (PWID). However, examples implementing such models in primary care are lacking, leaving a gap in our applied understanding of how practically we best scale-up such care: this is critical and urgent if the benefits of treatment advances are to be realized for PWID. A CASE STUDY: The Cool Aid Community Health Centre (CHC) provides HCV programming for PWID, putting recent advances into practice. A case study of the CHC's HCV programming describes the practice experience and outcomes of its novel, multidisciplinary, primary care, inner-city HCV treatment program for PWID. This paper describes how this model of care functions to address the many barriers to treatment and successfully facilitate adherence to treatment. CONCLUSION: Medical advances for HCV will be ineffectual without effective management of complex barriers to care related to substance use, mental health, trauma, poverty, homelessness, criminalization, cultural issues, stigma and marginalization. HCV treatment for PWIDs benefits from low-threshold settings which are culturally appropriate and where trusting relationships between clients and providers are nurtured. Public investment in primary care treatment for PWID living with HCV, including investments in supports that address the social barriers faced by these vulnerable populations would build on existing evidence and improve HCV outcomes for PWID.
BACKGROUND: Knowledge is increasing regarding effective models of HCV care for people who inject drugs (PWID). However, examples implementing such models in primary care are lacking, leaving a gap in our applied understanding of how practically we best scale-up such care: this is critical and urgent if the benefits of treatment advances are to be realized for PWID. A CASE STUDY: The Cool Aid Community Health Centre (CHC) provides HCV programming for PWID, putting recent advances into practice. A case study of the CHC's HCV programming describes the practice experience and outcomes of its novel, multidisciplinary, primary care, inner-city HCV treatment program for PWID. This paper describes how this model of care functions to address the many barriers to treatment and successfully facilitate adherence to treatment. CONCLUSION: Medical advances for HCV will be ineffectual without effective management of complex barriers to care related to substance use, mental health, trauma, poverty, homelessness, criminalization, cultural issues, stigma and marginalization. HCV treatment for PWIDs benefits from low-threshold settings which are culturally appropriate and where trusting relationships between clients and providers are nurtured. Public investment in primary care treatment for PWID living with HCV, including investments in supports that address the social barriers faced by these vulnerable populations would build on existing evidence and improve HCV outcomes for PWID.
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice Journal: Int J Drug Policy Date: 2017-08-12
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17
Authors: Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2016-07-04 Impact factor: 2.471
Authors: David A Wohl; Andrew G Allmon; Donna Evon; Christopher Hurt; Sarah Ailleen Reifeis; Harsha Thirumurthy; Becky Straub; Angela Edwards; Katie R Mollan Journal: Open Forum Infect Dis Date: 2017-05-05 Impact factor: 3.835
Authors: Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami Journal: Hepatol Commun Date: 2020-12-07